A012301: LoTAM Trial — Comparing Low-Dose Tamoxifen vs. Standard Endocrine Therapy for Early-Stage Hormone-Positive Breast Cancer

Study Overview:
LoTAM evaluates whether low-dose tamoxifen can be as effective as standard endocrine therapy in preventing recurrence for postmenopausal women with early-stage, hormone receptor-positive, HER2-negative breast cancer. Researchers are also assessing whether the lower dose reduces adverse events and improves treatment adherence.

Key Study Details:

• Phase & Design: Phase III, randomized

• Population: Postmenopausal women with early-stage HR+, HER2-negative breast cancer

• Treatment Arms: Low-dose tamoxifen vs. standard endocrine therapy

• Primary Objective: Prove non-inferiority in preventing recurrence

• Why It Matters: Low-dose regimens may minimize side effects, helping more women stay on treatment long-term.